

# David A Reardon

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/801158/publications.pdf>

Version: 2024-02-01

242  
papers

34,102  
citations

7672

79  
h-index

4511

177  
g-index

247  
all docs

247  
docs citations

247  
times ranked

31559  
citing authors

#	ARTICLE	IF	CITATIONS
1	Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated <i>MGMT</i> promoter: An international randomized phase III trial. <i>Neuro-Oncology</i> , 2023, 25, 123-134.	0.6	150
2	Activity of PD-1 blockade with nivolumab among patients with recurrent atypical/anaplastic meningioma: phase II trial results. <i>Neuro-Oncology</i> , 2022, 24, 101-113.	0.6	38
3	Designing Clinical Trials for Combination Immunotherapy: A Framework for Glioblastoma. <i>Clinical Cancer Research</i> , 2022, 28, 585-593.	3.2	18
4	A molecularly integrated grade for meningioma. <i>Neuro-Oncology</i> , 2022, 24, 796-808.	0.6	83
5	Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement. <i>Clinical Cancer Research</i> , 2022, 28, 594-602.	3.2	67
6	Temporal Muscle Thickness as a Prognostic Marker in Patients with Newly Diagnosed Glioblastoma: Translational Imaging Analysis of the CENTRIC EORTC 26071 and CORE Trials. <i>Clinical Cancer Research</i> , 2022, 28, 129-136.	3.2	25
7	Preface. <i>Hematology/Oncology Clinics of North America</i> , 2022, 36, xv-xvi.	0.9	0
8	Is There a Role for Immunotherapy in Central Nervous System Cancers?. <i>Hematology/Oncology Clinics of North America</i> , 2022, 36, 237-252.	0.9	5
9	Combined immunotherapy with controlled interleukin-12 gene therapy and immune checkpoint blockade in recurrent glioblastoma: An open-label, multi-institutional phase I trial. <i>Neuro-Oncology</i> , 2022, 24, 951-963.	0.6	44
10	Short-term outcomes associated with temozolomide or PCV chemotherapy for 1p/19q-codeleted WHO grade 3 oligodendrogliomas: A national evaluation. <i>Neuro-Oncology Practice</i> , 2022, 9, 201-207.	1.0	3
11	Nivolumab plus radiotherapy with or without temozolomide in newly diagnosed glioblastoma: Results from exploratory phase I cohorts of CheckMate 143. <i>Neuro-Oncology Advances</i> , 2022, 4, vda025.	0.4	18
12	Genomic Analysis of Tumors from Patients with Glioblastoma with Long-Term Response to Afatinib. <i>OncoTargets and Therapy</i> , 2022, Volume 15, 367-380.	1.0	0
13	Circulating Immune Cell and Outcome Analysis from the Phase II Study of PD-L1 Blockade with Durvalumab for Newly Diagnosed and Recurrent Glioblastoma. <i>Clinical Cancer Research</i> , 2022, 28, 2567-2578.	3.2	20
14	Clinical utility of targeted next-generation sequencing assay in IDH-wildtype glioblastoma for therapy decision-making. <i>Neuro-Oncology</i> , 2022, 24, 1140-1149.	0.6	13
15	Brain metastases: A Society for Neuro-Oncology (SNO) consensus review on current management and future directions. <i>Neuro-Oncology</i> , 2022, 24, 1613-1646.	0.6	39
16	Radiomics-Based Machine Learning for Outcome Prediction in a Multicenter Phase II Study of Programmed Death-Ligand 1 Inhibition Immunotherapy for Glioblastoma. <i>American Journal of Neuroradiology</i> , 2022, 43, 675-681.	1.2	12
17	DSP-0390, an oral emopamil binding protein (EBP) inhibitor, in patients with recurrent high-grade glioma: A first-in-human, phase 1 study. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS2077-TPS2077.	0.8	2
18	Concurrent Dexamethasone Limits the Clinical Benefit of Immune Checkpoint Blockade in Glioblastoma. <i>Clinical Cancer Research</i> , 2021, 27, 276-287.	3.2	100

#	ARTICLE	IF	CITATIONS
19	Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma. <i>Clinical Cancer Research</i> , 2021, 27, 1048-1057.	3.2	129
20	Adolescent and young adult neuro-oncology: a comprehensive review. <i>Neuro-Oncology Practice</i> , 2021, 8, 236-246.	1.0	5
21	The combined use of steroids and immune checkpoint inhibitors in brain metastasis patients: a systematic review and meta-analysis. <i>Neuro-Oncology</i> , 2021, 23, 1261-1272.	0.6	28
22	Clinical, radiological and genomic features and targeted therapy in BRAF V600E mutant adult glioblastoma. <i>Journal of Neuro-Oncology</i> , 2021, 152, 515-522.	1.4	18
23	IDH-mutant gliomas with additional class-defining molecular events. <i>Modern Pathology</i> , 2021, 34, 1236-1244.	2.9	13
24	Inhibitory CD161 receptor identified in glioma-infiltrating T cells by single-cell analysis. <i>Cell</i> , 2021, 184, 1281-1298.e26.	13.5	210
25	Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204). <i>Neuro-Oncology</i> , 2021, 23, 1961-1973.	0.6	66
26	The Current Landscape of Immune Checkpoint Blockade in Glioblastoma. <i>Neurosurgery Clinics of North America</i> , 2021, 32, 235-248.	0.8	8
27	Improved outcomes associated with maximal extent of resection for butterfly glioblastoma: insights from institutional and national data. <i>Acta Neurochirurgica</i> , 2021, 163, 1883-1894.	0.9	11
28	Vaccination for IDH-mutant tumors: A novel therapeutic approach applied to glioma. <i>Med</i> , 2021, 2, 450-452.	2.2	4
29	A Comparative Retrospective Study of Immunotherapy RANO Versus Standard RANO Criteria in Glioblastoma Patients Receiving Immune Checkpoint Inhibitor Therapy. <i>Frontiers in Oncology</i> , 2021, 11, 679331.	1.3	4
30	Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors. , 2021, 9, e002890.		87
31	Systematic review of combinations of targeted or immunotherapy in advanced solid tumors. , 2021, 9, e002459.		41
32	Glial and myeloid heterogeneity in the brain tumour microenvironment. <i>Nature Reviews Cancer</i> , 2021, 21, 786-802.	12.8	83
33	Glioblastoma as an age-related neurological disorder in adults. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab125.	0.4	30
34	Treatment with pembrolizumab in programmed death ligand 1 "positive recurrent glioblastoma: Results from the multicohort phase 1 KEYNOTE 028 trial. <i>Cancer</i> , 2021, 127, 1620-1629.	2.0	56
35	Unique challenges for glioblastoma immunotherapy" discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Meeting Report from the 2019 SNO Immuno-Oncology Think Tank. <i>Neuro-Oncology</i> , 2021, 23, 356-375.	0.6	59
36	Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study. <i>Lancet Oncology</i> , The, 2021, 22, 1692-1704.	5.1	129

#	ARTICLE	IF	CITATIONS
37	Predictors and early survival outcomes of maximal resection in WHO grade II 1p/19q-codeleted oligodendrogliomas. <i>Neuro-Oncology</i> , 2020, 22, 369-380.	0.6	13
38	An Online Calculator for the Prediction of Survival in Glioblastoma Patients Using Classical Statistics and Machine Learning. <i>Neurosurgery</i> , 2020, 86, E184-E192.	0.6	75
39	Socioeconomic Disparities Associated With <i>MGMT</i> Promoter Methylation Testing for Patients With Glioblastoma. <i>JAMA Oncology</i> , 2020, 6, 1972.	3.4	22
40	Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma. <i>JAMA Oncology</i> , 2020, 6, 1003.	3.4	805
41	A phase 1 study of PF-06840003, an oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor in patients with recurrent malignant glioma. <i>Investigational New Drugs</i> , 2020, 38, 1784-1795.	1.2	38
42	Adult immuno-oncology: using past failures to inform the future. <i>Neuro-Oncology</i> , 2020, 22, 1249-1261.	0.6	19
43	Blood-brain barrier disruption and delivery of irinotecan in a rat model using a clinical transcranial MRI-guided focused ultrasound system. <i>Scientific Reports</i> , 2020, 10, 8766.	1.6	24
44	Tumor Interferon Signaling Is Regulated by a lncRNA INCR1 Transcribed from the PD-L1 Locus. <i>Molecular Cell</i> , 2020, 78, 1207-1223.e8.	4.5	43
45	NRG/TOG 1122: A phase 2, double-blind, placebo-controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcoma. <i>Cancer</i> , 2020, 126, 2821-2828.	2.0	25
46	Glioblastoma infiltration of both tumor- and virus-antigen specific cytotoxic T cells correlates with experimental virotherapy responses. <i>Scientific Reports</i> , 2020, 10, 5095.	1.6	28
47	Deep Learning Detection of Cancer Metastases to the Brain on MRI. <i>Journal of Magnetic Resonance Imaging</i> , 2020, 52, 1227-1236.	1.9	71
48	Phase 0 and window of opportunity clinical trial design in neuro-oncology: a RANO review. <i>Neuro-Oncology</i> , 2020, 22, 1568-1579.	0.6	38
49	Emerging immunotherapies for malignant glioma: from immunogenomics to cell therapy. <i>Neuro-Oncology</i> , 2020, 22, 1425-1438.	0.6	37
50	Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. <i>Neuro-Oncology</i> , 2020, 22, 1073-1113.	0.6	543
51	Mechanisms and therapeutic implications of hypermutation in gliomas. <i>Nature</i> , 2020, 580, 517-523.	13.7	374
52	Optimizing eligibility criteria and clinical trial conduct to enhance clinical trial participation for primary brain tumor patients. <i>Neuro-Oncology</i> , 2020, 22, 601-612.	0.6	23
53	BIOM-44. GENOMIC PREDICTORS OF ADVERSE EVENTS IN NEWLY DIAGNOSED IDH-WILDTYPE GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2020, 22, ii11-ii11.	0.6	1
54	CTNI-11. CC-115 IN NEWLY DIAGNOSED MGMT UNMETHYLATED GLIOBLASTOMA IN THE INDIVIDUALIZED SCREENING TRIAL OF INNOVATIVE GLIOBLASTOMA THERAPY (INSIGHT): A PHASE II RANDOMIZED BAYESIAN ADAPTIVE PLATFORM TRIAL. <i>Neuro-Oncology</i> , 2020, 22, ii43-ii44.	0.6	3

#	ARTICLE	IF	CITATIONS
55	IMMU-09. CONCURRENT DEXAMETHASONE LIMITS THE CLINICAL BENEFIT OF IMMUNE CHECKPOINT BLOCKADE IN GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2020, 22, ii106-ii106.	0.6	1
56	CTNI-47. PHASE II STUDY OF ABEMACICLIB IN RECURRENT GBM PATIENTS WITH CDKN2A/B LOSS AND INTACT RB. <i>Neuro-Oncology</i> , 2020, 22, ii53-ii53.	0.6	1
57	CTNI-12. PRELIMINARY RESULTS OF THE ABEMACICLIB ARM IN THE INDIVIDUALIZED SCREENING TRIAL OF INNOVATIVE GLIOBLASTOMA THERAPY (INSIGHT): A PHASE II PLATFORM TRIAL USING BAYESIAN ADAPTIVE RANDOMIZATION. <i>Neuro-Oncology</i> , 2020, 22, ii44-ii44.	0.6	5
58	CTIM-12. RANDOMIZED PHASE 2 STUDY OF NIVOLUMAB (NIVO) PLUS EITHER STANDARD OR REDUCED DOSE BEVACIZUMAB (BEV) IN RECURRENT GLIOBLASTOMA (rGBM). <i>Neuro-Oncology</i> , 2020, 22, ii35-ii35.	0.6	0
59	BIOM-61. FUNCTIONAL DIAGNOSTIC TESTING OF LIVE-CELL DRUG RESPONSE USING 3D PATIENT DERIVED GLIOBLASTOMA SPHEROIDS ON THE INCUCYTE PLATFORM. <i>Neuro-Oncology</i> , 2020, 22, ii15-ii15.	0.6	0
60	CTIM-07. IDENTIFICATION OF A BASELINE BIOMARKER ASSOCIATED WITH TUMOR RESPONSES IN A PHASE I/IIa TRIAL OF A THERAPEUTIC CMV VACCINE AGAINST RECURRENT GLIOBLASTOMA (GBM). <i>Neuro-Oncology</i> , 2020, 22, ii34-ii34.	0.6	0
61	NCOG-44. NEUROLOGIC ASSESSMENT IN NEURO-ONCOLOGY (NANO) SCALE IN A PHASE II STUDY OF PEMBROLIZUMAB OR PEMBROLIZUMAB PLUS BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2020, 22, ii138-ii139.	0.6	0
62	EPID-35. CLINICAL TRIAL ENROLLMENT RATE AMONG ADOLESCENT AND YOUNG ADULTS WITH CENTRAL NERVOUS SYSTEM TUMOR AT DANA-FARBER CANCER INSTITUTE (DFCI). <i>Neuro-Oncology</i> , 2020, 22, ii86-ii86.	0.6	0
63	PATH-03. CLINICAL UTILITY OF NEXT GENERATION SEQUENCING IN IDH-WILDTYPE GLIOBLASTOMA: THE DANA-FARBER CANCER INSTITUTE EXPERIENCE. <i>Neuro-Oncology</i> , 2020, 22, ii164-ii164.	0.6	0
64	RADT-25. EVALUATING LYMPHOCYTE COUNTS IN NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS RECEIVING CHEMORADIATION. <i>Neuro-Oncology</i> , 2020, 22, ii186-ii187.	0.6	0
65	EPID-11. A MULTI-INSTITUTIONAL COMPARATIVE ANALYSIS OF THE CLINICAL, GENOMIC, AND SURVIVAL CHARACTERISTICS OF PEDIATRIC, YOUNG ADULT AND OLDER ADULT PATIENTS WITH IDH-MUTANT GLIOMA. <i>Neuro-Oncology</i> , 2020, 22, ii80-ii81.	0.6	1
66	CTIM-32. PHASE II AND BIOMARKER STUDY OF PEMBROLIZUMAB OR PEMBROLIZUMAB PLUS BEVACIZUMAB FOR RECURRENT GLIOBLASTOMA PATIENTS. <i>Neuro-Oncology</i> , 2020, 22, ii40-ii40.	0.6	0
67	BIOM-34. CLINICAL, RADIOGRAPHIC, AND PATHOLOGIC PREDICTORS OF RESPONSE TO ANTI-PD-1 AND ANTI-PD-L1 THERAPY IN IDH-WILDTYPE GLIOBLASTOMA PATIENTS. <i>Neuro-Oncology</i> , 2020, 22, ii8-ii9.	0.6	0
68	Proposed response assessment and endpoints for meningioma clinical trials: report from the Response Assessment in Neuro-Oncology Working Group. <i>Neuro-Oncology</i> , 2019, 21, 26-36.	0.6	114
69	Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: Results of a phase 1 trial. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	170
70	A Randomized Double-Blind Placebo-Controlled Phase II Trial of Dendritic Cell Vaccine ICT-107 in Newly Diagnosed Patients with Glioblastoma. <i>Clinical Cancer Research</i> , 2019, 25, 5799-5807.	3.2	166
71	Molecular targeted therapy of glioblastoma. <i>Cancer Treatment Reviews</i> , 2019, 80, 101896.	3.4	386
72	Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial. <i>Neuro-Oncology</i> , 2019, 21, 106-114.	0.6	84

#	ARTICLE	IF	CITATIONS
73	Acoustic feedback enables safe and reliable carboplatin delivery across the blood-brain barrier with a clinical focused ultrasound system and improves survival in a rat glioma model. <i>Theranostics</i> , 2019, 9, 6284-6299.	4.6	78
74	Safety, tolerability, and pharmacokinetics of anti-EGFRvIII antibody-drug conjugate AMG 595 in patients with recurrent malignant glioma expressing EGFRvIII. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 327-336.	1.1	38
75	Survival and prognostic factors in surgically treated brain metastases. <i>Journal of Neuro-Oncology</i> , 2019, 143, 359-367.	1.4	35
76	Efficacy and safety of immune checkpoint blockade for brain metastases. <i>CNS Oncology</i> , 2019, 8, CNS33.	1.2	16
77	Control of tumor-associated macrophages and T cells in glioblastoma via AHR and CD39. <i>Nature Neuroscience</i> , 2019, 22, 729-740.	7.1	327
78	Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. <i>Nature Medicine</i> , 2019, 25, 477-486.	15.2	932
79	Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. <i>Nature</i> , 2019, 565, 234-239.	13.7	956
80	The Misclassification of Diffuse Gliomas: Rates and Outcomes. <i>Clinical Cancer Research</i> , 2019, 25, 2656-2663.	3.2	42
81	Arming an Oncolytic Herpes Simplex Virus Type 1 with a Single-chain Fragment Variable Antibody against PD-1 for Experimental Glioblastoma Therapy. <i>Clinical Cancer Research</i> , 2019, 25, 290-299.	3.2	88
82	Toxicity and Efficacy of a Novel GADD34-expressing Oncolytic HSV-1 for the Treatment of Experimental Glioblastoma. <i>Clinical Cancer Research</i> , 2018, 24, 2574-2584.	3.2	40
83	Multiplexed immunofluorescence reveals potential PD-1/PD-L1 pathway vulnerabilities in craniopharyngioma. <i>Neuro-Oncology</i> , 2018, 20, 1101-1112.	0.6	67
84	Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma. <i>Neuro-Oncology</i> , 2018, 20, 1411-1418.	0.6	24
85	Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma. <i>Neuro-Oncology</i> , 2018, 20, 1240-1250.	0.6	64
86	Diagnostic accuracy of 2-hydroxyglutarate magnetic resonance spectroscopy in newly diagnosed brain mass and suspected recurrent gliomas. <i>Neuro-Oncology</i> , 2018, 20, 1262-1271.	0.6	31
87	Phase 2 and biomarker study of trebananib, an angiopoietin-blocking peptibody, with and without bevacizumab for patients with recurrent glioblastoma. <i>Cancer</i> , 2018, 124, 1438-1448.	2.0	38
88	Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas. <i>Journal of Neuro-Oncology</i> , 2018, 137, 349-356.	1.4	49
89	Modeling tumor immunity of mouse glioblastoma by exhausted CD8+ T cells. <i>Scientific Reports</i> , 2018, 8, 208.	1.6	24
90	Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143. <i>Neuro-Oncology</i> , 2018, 20, 674-686.	0.6	364

#	ARTICLE	IF	CITATIONS
91	Bevacizumab biosimilars: scientific justification for extrapolation of indications. <i>Future Oncology</i> , 2018, 14, 2507-2520.	1.1	32
92	Concepts for Immunotherapies in Gliomas. <i>Seminars in Neurology</i> , 2018, 38, 062-072.	0.5	26
93	Preclinical investigation of combined gene-mediated cytotoxic immunotherapy and immune checkpoint blockade in glioblastoma. <i>Neuro-Oncology</i> , 2018, 20, 225-235.	0.6	61
94	Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients with prior antiangiogenic therapy. <i>Neuro-Oncology</i> , 2018, 20, 259-267.	0.6	41
95	Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy. <i>Neuro-Oncology</i> , 2018, 20, 249-258.	0.6	78
96	Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma. <i>Neuro-Oncology</i> , 2018, 20, 838-847.	0.6	60
97	Neurological Complications of Immune-Based Therapies. , 2018, , 335-344.		0
98	Mismatch Repair Deficiency in High-Grade Meningioma: A Rare but Recurrent Event Associated With Dramatic Immune Activation and Clinical Response to PD-1 Blockade. <i>JCO Precision Oncology</i> , 2018, 1-12.	1.5	35
99	ATIM-38. PHASE 2 STUDY TO EVALUATE THE CLINICAL EFFICACY AND SAFETY OF MEDI4736 (DURVALUMAB,) Tj ETQq1 1 0.784314 r <i>Neuro-Oncology</i> , 2018, 20, vi10-vi10.	0.6	6
100	Pseudoprogression: fact or wishful thinking in neuro-oncology?. <i>Lancet Oncology</i> , The, 2018, 19, 1561-1563.	5.1	16
101	PD-1 inhibition has only limited clinical benefit in patients with recurrent high-grade glioma. <i>Neurology</i> , 2018, 91, e1355-e1359.	1.5	64
102	Corticosteroid use endpoints in neuro-oncology: Response Assessment in Neuro-Oncology Working Group. <i>Neuro-Oncology</i> , 2018, 20, 897-906.	0.6	41
103	Immunotherapy for glioblastoma: going viral. <i>Nature Medicine</i> , 2018, 24, 1094-1096.	15.2	25
104	Epidermal Growth Factor Receptor Extracellular Domain Mutations in Glioblastoma Present Opportunities for Clinical Imaging and Therapeutic Development. <i>Cancer Cell</i> , 2018, 34, 163-177.e7.	7.7	145
105	Improved Risk-Adjusted Survival for Melanoma Brain Metastases in the Era of Checkpoint Blockade Immunotherapies: Results from a National Cohort. <i>Cancer Immunology Research</i> , 2018, 6, 1039-1045.	1.6	60
106	CRAN-11. MULTIPLEXED IMMUNOFLOURESCENCE REVEALS POTENTIAL PD-1/PD-L1 PATHWAY VULNERABILITIES IN CRANIOPHARYNGIOMA. <i>Neuro-Oncology</i> , 2018, 20, i39-i39.	0.6	2
107	Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain. <i>New England Journal of Medicine</i> , 2018, 379, 722-730.	13.9	983
108	Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma. <i>Neuro-Oncology</i> , 2017, 19, now257.	0.6	80



#	ARTICLE	IF	CITATIONS
109	Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas. <i>Neuro-Oncology</i> , 2017, 19, now235.	0.6	99
110	Multimodal MRI features predict isocitrate dehydrogenase genotype in high-grade gliomas. <i>Neuro-Oncology</i> , 2017, 19, 109-117.	0.6	211
111	The development of dendritic cell vaccine-based immunotherapies for glioblastoma. <i>Seminars in Immunopathology</i> , 2017, 39, 225-239.	2.8	42
112	Advanced MRI assessment to predict benefit of anti-programmed cell death 1 protein immunotherapy response in patients with recurrent glioblastoma. <i>Neuroradiology</i> , 2017, 59, 135-145.	1.1	57
113	Vaccine-based immunotherapeutic approaches to gliomas and beyond. <i>Nature Reviews Neurology</i> , 2017, 13, 363-374.	4.9	125
114	Quantitative imaging biomarkers for risk stratification of patients with recurrent glioblastoma treated with bevacizumab. <i>Neuro-Oncology</i> , 2017, 19, 1688-1697.	0.6	84
115	Angiogenesis inhibitors in tackling recurrent glioblastoma. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 507-515.	1.1	28
116	The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria. <i>Neuro-Oncology</i> , 2017, 19, 625-635.	0.6	137
117	Immunomodulation for glioblastoma. <i>Current Opinion in Neurology</i> , 2017, 30, 361-369.	1.8	21
118	Salvage re-irradiation for recurrent high-grade glioma and comparison to bevacizumab alone. <i>Journal of Neuro-Oncology</i> , 2017, 135, 581-591.	1.4	15
119	Antibody-drug conjugates in glioblastoma therapy: the right drugs to the right cells. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 695-707.	12.5	90
120	ACTR-23. MOLECULAR GENETIC, HOST-DERIVED AND CLINICAL DETERMINANTS OF LONG-TERM SURVIVAL IN GLIOBLASTOMA: FIRST RESULTS FROM THE BRAIN TUMOR FUNDERS'™ COLLABORATIVE CONSORTIUM. <i>Neuro-Oncology</i> , 2017, 19, vi5-vi6.	0.6	0
121	High-grade Gliomas. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2017, 23, 1548-1563.	0.4	49
122	Immunotherapy for glioblastoma: on the sidelines or in the game?. <i>Discovery Medicine</i> , 2017, 24, 201-208.	0.5	31
123	Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors. <i>Oncotarget</i> , 2016, 7, 76565-76576.	0.8	100
124	Adult brainstem gliomas. <i>Cancer</i> , 2016, 122, 2799-2809.	2.0	35
125	Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas. <i>Cancer</i> , 2016, 122, 582-587.	2.0	33
126	Radiation therapy for glioblastoma: Executive summary of an American Society for Radiation Oncology Evidence-Based Clinical Practice Guideline. <i>Practical Radiation Oncology</i> , 2016, 6, 217-225.	1.1	162



#	ARTICLE	IF	CITATIONS
127	Multimodal imaging patterns predict survival in recurrent glioblastoma patients treated with bevacizumab. <i>Neuro-Oncology</i> , 2016, 18, 1680-1687.	0.6	94
128	A randomized, placebo-controlled pilot trial of armodafinil for fatigue in patients with gliomas undergoing radiotherapy. <i>Neuro-Oncology</i> , 2016, 18, 849-854.	0.6	45
129	The Clinical Implications of Inconsistently Methylated Results from Glioblastoma MGMT Testing by Replicate Methylation-Specific PCR. <i>Journal of Molecular Diagnostics</i> , 2016, 18, 864-871.	1.2	14
130	ACTR-07. EFFICACY OF A NOVEL ANTIBODY-DRUG CONJUGATE (ADC), ABT-414, AS MONOTHERAPY IN EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AMPLIFIED (EGFRamp), RECURRENT GLIOBLASTOMA (rGBM). <i>Neuro-Oncology</i> , 2016, 18, vi2-vi2.	0.6	1
131	Checkpoint inhibition in meningiomas. <i>Immunotherapy</i> , 2016, 8, 721-731.	1.0	22
132	Adult Atypical Teratoid/Rhabdoid Tumors. <i>World Neurosurgery</i> , 2016, 85, 197-204.	0.7	27
133	Glioblastoma in the elderly: making sense of the evidence. <i>Neuro-Oncology Practice</i> , 2016, 3, 77-86.	1.0	17
134	Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 731-739.	0.8	159
135	Oncogenic PI3K mutations are as common as <i>AKT1</i> and <i>SMO</i> mutations in meningioma. <i>Neuro-Oncology</i> , 2016, 18, 649-655.	0.6	221
136	The Impact of T2/FLAIR Evaluation per RANO Criteria on Response Assessment of Recurrent Glioblastoma Patients Treated with Bevacizumab. <i>Clinical Cancer Research</i> , 2016, 22, 575-581.	3.2	62
137	Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model. <i>Cancer Immunology Research</i> , 2016, 4, 124-135.	1.6	339
138	MAPK activation and <i>HRAS</i> mutation identified in pituitary spindle cell oncocytoma. <i>Oncotarget</i> , 2016, 7, 37054-37063.	0.8	27
139	ATCT-22NRG ONCOLOGY/RTOG 1122: PHASE II DOUBLE-BLINDED, PLACEBO-CONTROLLED STUDY OF BEVACIZUMAB WITH OR WITHOUT AMG 386 IN PATIENTS WITH RECURRENT GLIOBLASTOMA OR GLIOSARCOMA. <i>Neuro-Oncology</i> , 2015, 17, v6.2-v6.	0.6	2
140	Interpretation of meta-analysis evaluating progression-free survival as a surrogate endpoint for overall survival in glioblastoma. <i>Neuro-Oncology</i> , 2015, 17, 764-765.	0.6	0
141	Extent of resection and overall survival for patients with atypical and malignant meningioma. <i>Cancer</i> , 2015, 121, 4376-4381.	2.0	144
142	Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma. <i>Oncotarget</i> , 2015, 6, 4704-4716.	0.8	127
143	Phase II Trial of Upfront Bevacizumab, Irinotecan, and Temozolomide for Unresectable Glioblastoma. <i>Oncologist</i> , 2015, 20, 727-728.	1.9	32
144	Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma. <i>Neuro-Oncology</i> , 2015, 17, 862-867.	0.6	111

#	ARTICLE	IF	CITATIONS
145	Unravelling tumour heterogeneityâ€™ implications for therapy. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 69-70.	12.5	89
146	A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study. <i>Neuro-Oncology</i> , 2015, 17, 854-861.	0.6	335
147	Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma. <i>Neurology</i> , 2015, 84, 280-286.	1.5	92
148	Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. <i>Nature</i> , 2015, 519, 366-369.	13.7	429
149	Hypofractionated Versus Standard Radiation Therapy With or Without Temozolomide for Older Glioblastoma Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 384-389.	0.4	46
150	Multicentric Low-Grade Gliomas. <i>World Neurosurgery</i> , 2015, 84, 1045-1050.	0.7	5
151	Rindopepimut vaccine and bevacizumab combination therapy: improving survival rates in relapsed glioblastoma patients?. <i>Immunotherapy</i> , 2015, 7, 603-606.	1.0	13
152	Re-defining response and treatment effects for neuro-oncology immunotherapy clinical trials. <i>Journal of Neuro-Oncology</i> , 2015, 123, 339-346.	1.4	10
153	Clinical implementation of integrated whole-genome copy number and mutation profiling for glioblastoma. <i>Neuro-Oncology</i> , 2015, 17, 1344-1355.	0.6	40
154	Brachytherapy in the treatment of recurrent aggressive falxine meningiomas. <i>Journal of Neuro-Oncology</i> , 2015, 124, 515-522.	1.4	10
155	Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. <i>Lancet Oncology</i> , The, 2015, 16, e534-e542.	5.1	582
156	Immunotherapy for neuro-oncology: the critical rationale for combinatorial therapy. <i>Neuro-Oncology</i> , 2015, 17, vii32-vii40.	0.6	21
157	Prospects of immune checkpoint modulators in the treatment of glioblastoma. <i>Nature Reviews Neurology</i> , 2015, 11, 504-514.	4.9	307
158	An Update on the Role of Immunotherapy and Vaccine Strategies for Primary Brain Tumors. <i>Current Treatment Options in Oncology</i> , 2015, 16, 54.	1.3	44
159	Rapid Intraoperative Molecular Characterization of Glioma. <i>JAMA Oncology</i> , 2015, 1, 662.	3.4	68
160	Medical management of brain tumors and the sequelae of treatment. <i>Neuro-Oncology</i> , 2015, 17, 488-504.	0.6	114
161	Afatinib, an irreversible ErbB family blocker, with protracted temozolomide in recurrent glioblastoma: A case report. <i>Oncotarget</i> , 2015, 6, 34030-34037.	0.8	17
162	One size should not fit all: advancing toward personalized glioblastoma therapy. <i>Discovery Medicine</i> , 2015, 19, 471-7.	0.5	13

#	ARTICLE	IF	CITATIONS
163	Impact of imaging measurements on response assessment in glioblastoma clinical trials. <i>Neuro-Oncology</i> , 2014, 16, vii24-vii35.	0.6	32
164	Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD). <i>Neuro-Oncology</i> , 2014, 16, vii36-vii47.	0.6	41
165	Targeted molecular therapies against epidermal growth factor receptor: Past experiences and challenges. <i>Neuro-Oncology</i> , 2014, 16, viii7-viii13.	0.6	85
166	Further delineating bevacizumab's response spectrum. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 243-244.	12.5	0
167	Antiangiogenic Therapy for Glioblastoma: Current Status and Future Prospects. <i>Clinical Cancer Research</i> , 2014, 20, 5612-5619.	3.2	129
168	Retrospective study of carmustine or lomustine with bevacizumab in recurrent glioblastoma patients who have failed prior bevacizumab. <i>Neuro-Oncology</i> , 2014, 16, 1523-1529.	0.6	22
169	Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 1100-1108.	5.1	800
170	Immunotherapy advances for glioblastoma. <i>Neuro-Oncology</i> , 2014, 16, 1441-1458.	0.6	164
171	Adjuvant radiation therapy, local recurrence, and the need for salvage therapy in atypical meningioma. <i>Neuro-Oncology</i> , 2014, 16, 1547-1553.	0.6	80
172	AT-36PANOBINOSTAT IN COMBINATION WITH BEVACIZUMAB FOR RECURRENT GLIOBLASTOMA AND ANAPLASTIC GLIOMA. <i>Neuro-Oncology</i> , 2014, 16, v16-v16.	0.6	0
173	Clinical multiplexed exome sequencing distinguishes adult oligodendroglial neoplasms from astrocytic and mixed lineage gliomas. <i>Oncotarget</i> , 2014, 5, 8083-8092.	0.8	55
174	Low-dose whole brain radiotherapy combined with radiosurgery for primary CNS lymphoma achieving partial response to induction methotrexate-based chemotherapy. <i>Journal of Radiosurgery and SBRT</i> , 2014, 3, 37-42.	0.2	3
175	Update on bevacizumab and other angiogenesis inhibitors for brain cancer. <i>Expert Opinion on Emerging Drugs</i> , 2013, 18, 137-153.	1.0	29
176	Treatment Options in Newly Diagnosed Glioblastoma. <i>Current Treatment Options in Neurology</i> , 2013, 15, 281-288.	0.7	10
177	An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma. <i>Expert Review of Vaccines</i> , 2013, 12, 597-615.	2.0	60
178	A Phase I/II Trial of Pazopanib in Combination with Lapatinib in Adult Patients with Relapsed Malignant Glioma. <i>Clinical Cancer Research</i> , 2013, 19, 900-908.	3.2	112
179	Antiangiogenic Therapy for Glioblastoma: The Challenge of Translating Response Rate into Efficacy. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, , e71-e78.	1.8	5
180	Response to C. Massard et al. <i>Journal of Clinical Oncology</i> , 2012, 30, 563-564.	0.8	0

#	ARTICLE	IF	CITATIONS
181	Treatment of elderly patients with glioblastoma. <i>Lancet Oncology</i> , The, 2012, 13, 656-657.	5.1	6
182	A dose escalation trial for the combination of erlotinib and sirolimus for recurrent malignant gliomas. <i>Journal of Neuro-Oncology</i> , 2012, 110, 245-250.	1.4	17
183	A Pilot Study of IL-2R $\alpha$ Blockade during Lymphopenia Depletes Regulatory T-cells and Correlates with Enhanced Immunity in Patients with Glioblastoma. <i>PLoS ONE</i> , 2012, 7, e31046.	1.1	98
184	Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma. <i>Cancer</i> , 2012, 118, 4759-4767.	2.0	26
185	Phase I trial of dasatinib plus erlotinib in adults with recurrent malignant glioma. <i>Journal of Neuro-Oncology</i> , 2012, 108, 499-506.	1.4	41
186	Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series. <i>Journal of Neuro-Oncology</i> , 2012, 109, 63-70.	1.4	172
187	Ridaforolimus for patients with progressive or recurrent malignant glioma: a perisurgical, sequential, ascending-dose trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 849-860.	1.1	18
188	Phase I study of AEE788, a novel multitarget inhibitor of ErbB- and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 1507-1518.	1.1	59
189	Pharmacokinetic drug interaction between AEE788 and RAD001 causing thrombocytopenia in patients with glioblastoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 281-287.	1.1	11
190	Phase II study of Gleevec <sup>®</sup> plus hydroxyurea (HU) in adults with progressive or recurrent meningioma. <i>Journal of Neuro-Oncology</i> , 2012, 106, 409-415.	1.4	78
191	Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2012, 107, 155-164.	1.4	123
192	Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients. <i>Journal of Neuro-Oncology</i> , 2012, 107, 213-221.	1.4	24
193	Vorinostat, temozolomide, and bevacizumab for patients with recurrent glioblastoma: A phase I/II trial. <i>Journal of Clinical Oncology</i> , 2012, 30, 2027-2027.	0.8	1
194	Phase II study of bevacizumab plus irinotecan and carboplatin for recurrent WHO grade 3 malignant gliomas with no prior bevacizumab failure. <i>Journal of Clinical Oncology</i> , 2012, 30, 2095-2095.	0.8	0
195	Safety and efficacy of the addition of bevacizumab to temozolomide and radiation therapy followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma multiforme. <i>Journal of Clinical Oncology</i> , 2012, 30, 2094-2094.	0.8	15
196	The addition of bevacizumab to temozolomide and radiation therapy followed by bevacizumab, temozolomide, and oral topotecan for newly diagnosed glioblastoma multiforme (GBM). <i>Journal of Clinical Oncology</i> , 2012, 30, 2090-2090.	0.8	1
197	Cilengitide: an RGD pentapeptide $\alpha$ 5 $\beta$ 3 and $\alpha$ 5 $\beta$ 1 integrin inhibitor in development for glioblastoma and other malignancies. <i>Future Oncology</i> , 2011, 7, 339-354.	1.1	98
198	Monoclonal antibody blockade of IL-2 receptor $\alpha$ during lymphopenia selectively depletes regulatory T cells in mice and humans. <i>Blood</i> , 2011, 118, 3003-3012.	0.6	104

#	ARTICLE	IF	CITATIONS
199	A Review of VEGF/VEGFR-Targeted Therapeutics for Recurrent Glioblastoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011, 9, 414-427.	2.3	113
200	Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2011, 101, 57-66.	1.4	118
201	Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. <i>Journal of Neuro-Oncology</i> , 2011, 103, 371-379.	1.4	83
202	Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma. <i>Journal of Neuro-Oncology</i> , 2011, 105, 621-627.	1.4	62
203	Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. <i>Cancer</i> , 2011, 117, 5351-5358.	2.0	80
204	Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRVIII-expressing tumor cells in patients with glioblastoma. <i>Neuro-Oncology</i> , 2011, 13, 324-333.	0.6	306
205	Cilengitide: A Prototypic Integrin Inhibitor for the Treatment of Glioblastoma and Other Malignancies. <i>Genes and Cancer</i> , 2011, 2, 1159-1165.	0.6	63
206	Advances in malignant glioma drug discovery. <i>Expert Opinion on Drug Discovery</i> , 2011, 6, 739-753.	2.5	16
207	Clinical trial end points for high-grade glioma: the evolving landscape. <i>Neuro-Oncology</i> , 2011, 13, 353-361.	0.6	105
208	Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2010, 96, 219-230.	1.4	208
209	Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma. <i>Journal of Clinical Oncology</i> , 2010, 28, 4722-4729.	0.8	702
210	Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. <i>Neuro-Oncology</i> , 2010, 12, 1300-1310.	0.6	207
211	Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study. <i>Neuro-Oncology</i> , 2010, 12, 1061-1070.	0.6	112
212	Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group. <i>Journal of Clinical Oncology</i> , 2010, 28, 1963-1972.	0.8	3,222
213	Targeting multiple kinases in glioblastoma multiforme. <i>Expert Opinion on Investigational Drugs</i> , 2009, 18, 277-292.	1.9	39
214	An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 2773-2779.	1.9	262
215	Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma. <i>Cancer</i> , 2009, 115, 2188-2198.	2.0	79
216	Tinzaparin prophylaxis against venous thromboembolic complications in brain tumor patients. <i>Journal of Neuro-Oncology</i> , 2009, 95, 129-134.	1.4	47

#	ARTICLE	IF	CITATIONS
217	Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy. <i>Journal of Neuro-Oncology</i> , 2009, 95, 393-400.	1.4	53
218	<i>IDH1</i> and <i>IDH2</i> Mutations in Gliomas. <i>New England Journal of Medicine</i> , 2009, 360, 765-773.	13.9	5,285
219	The Emerging Role of Anti-Angiogenic Therapy for Malignant Glioma. <i>Current Treatment Options in Oncology</i> , 2008, 9, 1-22.	1.3	32
220	Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy. <i>Expert Opinion on Biological Therapy</i> , 2008, 8, 541-553.	1.4	73
221	Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: Phase 1 trial in adults with malignant glioma. <i>Neuro-Oncology</i> , 2008, 10, 330-340.	0.6	41
222	Bevacizumab Plus Irinotecan in Recurrent WHO Grade 3 Malignant Gliomas. <i>Clinical Cancer Research</i> , 2008, 14, 7068-7073.	3.2	166
223	Randomized Phase II Study of Cilengitide, an Integrin-Targeting Arginine-Glycine-Aspartic Acid Peptide, in Recurrent Glioblastoma Multiforme. <i>Journal of Clinical Oncology</i> , 2008, 26, 5610-5617.	0.8	448
224	A pilot study: 131I-Antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost. <i>Neuro-Oncology</i> , 2008, 10, 182-189.	0.6	95
225	Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme. <i>Expert Opinion on Investigational Drugs</i> , 2008, 17, 1225-1235.	1.9	174
226	Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme. <i>Journal of Clinical Oncology</i> , 2007, 25, 4722-4729.	0.8	1,285
227	Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma. <i>Clinical Cancer Research</i> , 2007, 13, 1253-1259.	3.2	1,005
228	Antitenascin-C monoclonal antibody radioimmunotherapy for malignant glioma patients. <i>Expert Review of Anticancer Therapy</i> , 2007, 7, 675-687.	1.1	68
229	Molecularly targeted therapy for malignant glioma. <i>Cancer</i> , 2007, 110, 13-24.	2.0	292
230	Recent Advances in the Treatment of Malignant Astrocytoma. <i>Journal of Clinical Oncology</i> , 2006, 24, 1253-1265.	0.8	285
231	Glioblastoma—more questions than answers?. <i>Nature Clinical Practice Oncology</i> , 2006, 3, 60-61.	4.3	2
232	Salvage Radioimmunotherapy With Murine Iodine-131-Labeled Antitenascin Monoclonal Antibody 81C6 for Patients With Recurrent Primary and Metastatic Malignant Brain Tumors: Phase II Study Results. <i>Journal of Clinical Oncology</i> , 2006, 24, 115-122.	0.8	186
233	Therapeutic Advances in the Treatment of Glioblastoma: Rationale and Potential Role of Targeted Agents. <i>Oncologist</i> , 2006, 11, 152-164.	1.9	206
234	Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial results. <i>Journal of Nuclear Medicine</i> , 2006, 47, 912-8.	2.8	32

#	ARTICLE	IF	CITATIONS
235	Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma. <i>Cancer</i> , 2005, 103, 329-338.	2.0	116
236	Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma. <i>Cancer</i> , 2005, 104, 1478-1486.	2.0	76
237	Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. <i>Molecular Cancer Therapeutics</i> , 2005, 4, 101-12.	1.9	176
238	Phase II Trial of Gefitinib in Recurrent Glioblastoma. <i>Journal of Clinical Oncology</i> , 2004, 22, 133-142.	0.8	677
239	Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma. <i>Neuro-Oncology</i> , 2004, 6, 134-144.	0.6	42
240	Irinotecan: promising activity in the treatment of malignant glioma. <i>Oncology</i> , 2003, 17, 9-14.	0.4	8
241	Phase II Trial of Murine <sup>131</sup> I-Labeled Antitenascin Monoclonal Antibody 81C6 Administered Into Surgically Created Resection Cavities of Patients With Newly Diagnosed Malignant Gliomas. <i>Journal of Clinical Oncology</i> , 2002, 20, 1389-1397.	0.8	227
242	The Current State of Glioma Data Registries. <i>Neuro-Oncology Advances</i> , 0, , .	0.4	1